Blog Posts
CBSA: Life Sciences M&A Fuels Growth & Innovation in Colorado
In a recent blog post, PULSE partner Colorado Bioscience Association (CBSA) highlighted the fundamental role of pro-innovation mergers and acquisitions in driving life sciences innovation and economic growth in Colorado and beyond.
Latest Estimates Reinforce Burden of FTC’s Final HSR Rule
The Federal Trade Commission (FTC)’s recently finalized Hart-Scott-Rodino (HSR) premerger notification rule places a significant time and cost burden on companies engaging in pro-competitive mergers and acquisitions (M&A), according to top legal analyses and the Agency’s own estimates.
National Venture Capital Association: FTC’s Enforcement Approach is Chilling Critical Investment in New Breakthroughs
The Federal Trade Commission (FTC)’s aggressive approach to mergers and acquisitions enforcement (M&A) is disrupting critical investment in innovation, according to National Venture Capital Association (NVCA) President Bobby Franklin, in an interview with Axios.
What They Are Saying: FTC’s Final HSR Premerger Rules Place Undue Burden on Competitive M&A Across Life Sciences
Leading organizations are expressing concern about the impact of the Federal Trade Commission (FTC)’s final Hart-Scott-Rodino (HSR) premerger notification rule, including the chilling effect it could have on biopharmaceutical and life sciences innovation.
PULSE Campaign Statement on Final HSR Rules
The Partnership for the U.S. Life Science Ecosystem (PULSE) in response to the final Hart-Scott-Rodino (HSR) premerger notification rules released today by the Federal Trade Commission (FTC).
Bloomberg Law: “Chilling Effect” of FTC & DOJ’s Aggressive M&A Enforcement Approach
The Federal Trade Commission (FTC) and Department of Justice (DOJ)’s aggressive approach towards mergers and acquisitions (M&A) is deterring companies from pursuing deals, write Bloomberg Law reporters Justin Wise and Mahira Dayal – threatening even procompetitive deals that pose no antitrust harms.
Innovations Advanced by M&A: A First-In-Class Treatment for Hypertrophic Cardiomyopathy
Mergers and acquisitions (M&A) are a vital mechanism for transitioning treatments currently in development to approved medicines available to the patients who need them the most. In one such example, the synergies from a life science acquisition brought a revolutionary therapy for hypertrophic cardiomyopathy (HCM) to patients.
Concurrences Law & Economics: Life Sciences M&A Brings Together Complementary Resources, Expertise
For life science companies of all sizes, competitive mergers and acquisitions (M&A) serve as a critical driver in bringing new and groundbreaking treatments and cures to market. In a recent article published in Concurrences Law and Economics, economists from Cornerstone Research highlight the many ways in which M&A supports biopharmaceutical innovation.
CSIS Report: Supporting Pro-Competitive M&A Is Critical to U.S. Leadership in Biopharmaceutical Innovation
Protecting and promoting collaboration across the U.S. life sciences ecosystem remains a driving force in bringing new breakthroughs to patients, according to a recent report from the Center for Strategic and International Studies (CSIS).
ABA Antitrust Podcast: Balanced Approach is Critical to Assessing the Impact of Life Sciences M&A on Innovation
On a recent episode of the ABA Antitrust Podcast Our Curious Amalgam, Dr. Penka Kovacheva, Cornerstone Research Vice President and lead author of a paper recently published in Concurrences, “The Impact of Pharmaceutical M&A on Innovation,” discusses many ways in which mergers and acquisitions (M&A) can contribute to biopharmaceutical innovation.